GNMSF (Genmab AS) Tariff Resilience Score: 8/10 (As of Jul. 07, 2026)


GNMSF Genmab AS GNMSF
93 GF Score
Price $282.16
GF Value $354.50
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Tariff Resilience Score?

Genmab AS GNMSF +2.60% 93 Tariff Resilience Score is 8 as of Jul. 07, 2026. GuruFocus rates GNMSF with a GF Score™ of 93/100 and a GF Value™ of $354.50 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,368 Biotechnology companies, Genmab AS ranks better than 98.68% on this metric.

Genmab AS has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Genmab AS has Genmab's operations are primarily in biotech, with limited exposure to tariffs. Its supply chain is less dependent on raw materials subject to tariffs, and its revenue is driven by licensing and partnerships, reducing direct tariff impact. Historical tariff changes have had minimal effect.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Genmab AS might have Highly Resilient.

Genmab AS  (OTCPK:GNMSF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Genmab AS Tariff Resilience Score Related Terms

GNMSF vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Genmab AS's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab AS Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Genmab AS's Tariff Resilience Score falls into.


GNMSF
93GF Score
Genmab AS GNMSF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Genmab AS (GNMSF) has a Tariff Resilience Score of 8 as of Jul. 07, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Genmab AS ranks #18 out of 1368 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Genmab AS's Tariff Resilience Score too high?
Genmab AS's current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Genmab AS's value of 8 is 100% above this industry median. Based on the distribution chart, Genmab AS ranks #18 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genmab AS has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #18 out of 1368 companies for Tariff Resilience Score. This places Genmab AS in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Genmab AS's value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genmab AS's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GNMSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $354.50, compared to a current price of $282.16 — trading 20.4% below its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Genmab AS's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Genmab AS (GNMSF), the current Tariff Resilience Score is 8 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (GNMSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of $282.16 is trading 20.4% below its estimated GF Value™ of $354.50. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for GNMSF:

  • Tariff Resilience Score: 8
  • GF Value™: $354.50 vs. price of $282.16 (20.4% below fair value)
  • GF Score™: 93/100 with 5 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1368)

No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score

Get the complete analysis for GNMSF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$282.16
Price
$354.50
GF Value